Cullinan Oncology Correlations
| CGEM Stock | USD 7.52 0.01 0.13% |
The current 90-days correlation between Cullinan Oncology LLC and Monte Rosa Therapeutics is 0.59 (i.e., Very weak diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cullinan Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cullinan Oncology LLC moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Cullinan Oncology Correlation With Market
Weak diversification
The correlation between Cullinan Oncology LLC and DJI is 0.37 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cullinan Oncology LLC and DJI in the same portfolio, assuming nothing else is changed.
Moving together with Cullinan Stock
Moving against Cullinan Stock
| 0.42 | BAC-PL | Bank of America | PairCorr |
| 0.4 | NKTR | Nektar Therapeutics | PairCorr |
| 0.38 | KMDA | Kamada | PairCorr |
| 0.5 | WFC-PL | Wells Fargo | PairCorr |
| 0.49 | INTC | Intel Earnings Call This Week | PairCorr |
| 0.34 | HPQ | HP Inc | PairCorr |
Related Correlations Analysis
| 0.53 | 0.67 | 0.67 | -0.05 | 0.5 | GLUE | ||
| 0.53 | 0.56 | 0.11 | 0.49 | 0.33 | DSGN | ||
| 0.67 | 0.56 | 0.25 | 0.47 | 0.63 | ERAS | ||
| 0.67 | 0.11 | 0.25 | -0.35 | 0.27 | VOR | ||
| -0.05 | 0.49 | 0.47 | -0.35 | 0.17 | BCAB | ||
| 0.5 | 0.33 | 0.63 | 0.27 | 0.17 | IMCR | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cullinan Stock performing well and Cullinan Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cullinan Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | 3.11 | 0.26 | 0.09 | 0.29 | 3.54 | 7.85 | 21.39 | |||
| DSGN | 3.93 | 0.22 | 0.05 | 0.28 | 5.04 | 8.13 | 27.45 | |||
| ERAS | 3.85 | 0.35 | 0.07 | 0.42 | 4.68 | 7.09 | 40.51 | |||
| VOR | 11.35 | 3.17 | 0.22 | 1.58 | 12.09 | 39.79 | 83.60 | |||
| BCAB | 4.47 | 0.10 | 0.02 | 0.22 | 4.32 | 12.00 | 34.01 | |||
| IMCR | 2.24 | 0.38 | 0.13 | 0.60 | 2.29 | 4.95 | 16.38 |
Cullinan Oncology Corporate Management
| Jennifer Michaelson | Chief Officer | Profile | |
| Kerry Whalen | Director Devel | Profile | |
| Jeffrey Trigilio | CFO Treasurer | Profile | |
| Mary Fenton | Chief Officer | Profile | |
| Jacquelyn JD | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile | |
| Nicholas Smith | Head Relations | Profile |